Min Lian, MD, PhD

CONTACT

Lead Sponsor

RenJi Hospital

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

•Age above 18 years old, Male or Female,
•Diagnosis of PBC meeting the 2018 American Association for the Study of Liver Diseases (AASLD) Practice Guidelines criteria;
•Treatment with UDCA at a standard dose (13-15 mg/kg/day), with or without other second-line medications.

•Co-existing liver diseases, including but not limited to: Hepatitis C virus infection; Active Hepatitis B infection (patients who are HBsAg-negative and HBeAg-negative may be considered eligible per investigator assessment);
•Autoimmune Hepatitis (AIH); Primary Sclerosing Cholangitis (PSC); Suspected or confirmed hepatocellular carcinoma;
•Female subjects who is pregnant or breastfeeding during the study;
•History of other malignancies, including hematological tumors, solid tumors except hepatobiliary system;
•Poor adherence or inability to complete the study follow-up.